The estimated Net Worth of Alton B Kremer is at least $134 Thousand dollars as of 1 April 2008. Alton Kremer owns over 3,153 units of Progenics Pharmaceuticals stock worth over $115,501 and over the last 19 years Alton sold PGNX stock worth over $18,900.
Alton has made over 13 trades of the Progenics Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently Alton exercised 3,153 units of PGNX stock worth $20,558 on 1 April 2008.
The largest trade Alton's ever made was exercising 8,000 units of Progenics Pharmaceuticals stock on 30 January 2006 worth over $108,560. On average, Alton trades about 1,357 units every 51 days since 2005. As of 1 April 2008 Alton still owns at least 28,171 units of Progenics Pharmaceuticals stock.
You can see the complete history of Alton Kremer stock trades at the bottom of the page.
Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over $11,559,939 worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth $11,900,148 . The most active insiders traders include Healthcare Master Fund Ltd ..., Michael D Kishbauch, and Bradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of $60,241. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth $359,395.
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
Progenics Pharmaceuticals executives and other stock owners filed with the SEC include: